Issues related to recent dengue vaccine development

Tropical Medicine and Health

Volumn 39, Issue 4 SUPPL., 2011, Pages 63-71

  Konishi, Eiji ^a,b,c  

^a KOBE UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Dengue; Enhancing antibody; Neutralizing antibody; Vaccine

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS PROTEIN;

3' UNTRANSLATED REGION; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL FEATURE; DENGUE; DENGUE VIRUS; DISEASE MODEL; DRUG DESIGN; DRUG RESEARCH; ENDEMIC DISEASE; HUMAN; INCIDENCE; INFECTION RATE; MEMORY T LYMPHOCYTE; MOLECULAR PHYLOGENY; MOSQUITO; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; VACCINATION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

EID: 84863826505     PISSN: 13488945     EISSN: 13494147     Source Type: Journal    
DOI: 10.2149/tmh.2011-S01     Document Type: Review

References (112)

1. Halstead SB. Dengue. Lancet 2007; 370: 1644-1652.
2. Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Willkins; 2007. p. 1153-1252.
3. Halstead SB, Vaughn DW. Dengue vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Maryland Heights: Saunders Elsevier; 2008. p. 1155-1161.
4. Widman DG, Frolov I, Mason PW. Third-generation flavivirus vaccines based on single-cycle, encapsidationdefective viruses. Adv Virus Res 2008; 72: 77-126.
5. Raviprakash K, Defang G, Burgess T, Porter K. Advances in dengue vaccine development. Hum Vaccin 2009; 5: 520-528.
6. Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010; 338: 129-143.
7. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009; 9: 678-687.
8. Miller N. Recent progress in dengue vaccine research and development. Curr Opin Mol Ther 2010; 12: 31-38.
9. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Pat 2010; 20: 819-835.
10. Whitehead SS, Durbin AP. Prospects and challenges for dengue virus vaccine development. In: Hanley KA, Weaver SC, eds. Frontiers in Dengue Virus Research. Norfolk UK: Caister Academic Press; 2010. p. 221-237.
11. Cui F, Raymond M, Qiao CL. Insecticide resistance in vector mosquitoes in China. Pest Manag Sci 2006; 62: 1013-1022.
12. Llinás GA, Seccacini E, Gardenal CN, Licastro S. Current resistance status to temephos in Aedes aegypti from different regions of Argentina. Mem Inst Oswaldo Cruz 2010; 105: 113-116.
13. García GP, Flores AE, Fernández-Salas I, Saavedra-Rodríguez K, Reyes-Solis G, Lozano-Fuentes S, Guillermo Bond J, Casas-Martínez M, Ramsey JM, García-Rejón J, Domínguez-Galera M, Ranson H, Hemingway J, Eisen L, Black IV WC. Recent rapid rise of a permethrin knock down resistance allele in Aedes aegypti in México. PLoS Negl Trop Dis 2009; 3: e531.
14. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Willkins; 2007. p. 1101-1152.
15. Westaway EG, Blok J. Taxonomy and evolutionary relationships of flaviviruses. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. New York: CABI Publishing; 1997. p. 147-173.
16. Gubler DJ. Arboviruses as imported disease agents: the need for increased awareness. Arch Virol Suppl 1996; 11: 21-32.
17. The number of Japanese nationals leaving Japan, The Ministry of Justice. http: //www.moj.go.jp/ENGLISH/IB/ ib-01.html
18. Information of dengue virus infections, National Institute of Infectious Diseases. http://www.nih.go.jp/vir1/NVL/ dengue.htm
19. Bennett SN. Evolutionary dynamics of dengue virus. In: Hanley KA, Weaver SC, eds. Frontiers in dengue virus research. Norfolk, UK: Caister Academic Press; 2010. p. 157-172.
20. Salda LT, Parquet MD, Matias RR, Natividad FF, Kobayashi N, Morita K. Molecular epidemiology of dengue 2 viruses in the Philippines: genotype shift and local evolution. Am J Trop Med Hyg 2005; 73: 796-802.
21. Zhang C, Mammen MP Jr, Chinnawirotpisan P, Klungthong C, Rodpradit P, Monkongdee P, Nimmannitya S, Kalayanarooj S, Holmes EC. Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol 2005; 79: 15123-15130.
22. Myat Thu H, Lowry K, Jiang L, Hlaing T, Holmes EC, Aaskov J. Lineage extinction and replacement in dengue type 1 virus populations are due to stochastic events rather than to natural selection. Virology 2005; 336: 163-172.
23. Aquino JD, Tang WF, Ishii R, Ono T, Eshita Y, Aono H, Makino Y. Molecular epidemiology of dengue virus serotypes 2 and 3 in Paraguay during 2001-2006: the association of viral clade introductions with shifting serotype dominance. Virus Res 2008; 137: 266-270.
24. Shu PY, Su CL, Liao TL, Yang CF, Chang SF, Lin CC, Chang MC, Hu HC, Huang JH. Molecular characterization of dengue viruses imported into Taiwan during 2003-2007: geographic distribution and genotype shift. Am J Trop Med Hyg 2009; 80: 1039-1046.
25. Kumar SR, Patil JA, Cecilia D, Cherian SS, Barde PV, Walimbe AM, Yadav PD, Yergolkar PN, Shah PS, Padbidri VS, Mishra AC, Mourya DT. Evolution, dispersal and replacement of American genotype dengue type 2 viruses in India (1956-2005): selection pressure and molecular clock analyses. J Gen Virol 2010; 91: 707-720.
26. Li DS, Liu W, Guigon A, Mostyn C, Grant R, Aaskov J. Rapid displacement of dengue virus type 1 by type 4, Pacific region, 2007-2009. Emerg Infect Dis 2010; 16: 123-125.
27. Weaver SC. Host range, amplification and arboviral disease emergence. Arch Virol Suppl 2005; 19: 33-44.
28. Yamada K, Takasaki T, Nawa M, Kurane I. Virus isolation as one of the diagnostic methods for dengue virus infection. J Clin Virol 2002; 24: 203-209.
29. Ooi Y, Hayashi A, Aoki H, Eda J, Hamada M, Imura S, et al. Viral Titers in the Sera of Dengue Patients among Travelers at the Quarantine Station of Kansai International Airport. Jpn J Infect Dis 2008; 6: 329-330.
30. Rosen L, Shroyer DA, Tesh RB, Freier JE, Lien JC. Transovarial transmission of dengue viruses by mosquitoes: Aedes albopictus and Aedes aegypti. Am J Trop Med Hyg 1983; 32: 1108-1119.
31. Rosen L. Mechanism of vertical transmission of the dengue virus in mosquitoes. C R Acad Sci III 1987; 304: 347-350.
32. Günther J, Martínez-Muñoz JP, Pérez-Ishiwara DG, Salas-Benito J. Evidence of vertical transmission of dengue virus in two endemic localities in the state of Oaxaca, Mexico. Intervirology 2007; 50: 347-352.
33. Angel B, Joshi V. Distribution and seasonality of vertically transmitted dengue viruses in Aedes mosquitoes in arid and semi-arid areas of Rajasthan, India. J Vector Borne Dis 2008; 45: 56-59.
34. Zeidler JD, Acosta PO, Barrêto PP, Cordeiro Jda S. Dengue virus in Aedes aegypti larvae and infestation dynamics in Roraima, Brazil. Rev Saude Publica 2008; 42: 986-991.
35. Guedes DR, Cordeiro MT, Melo-Santos MA, Magalhaes T, Marques E, Regis L, Furtado AF, Ayres CF. Patient-based dengue virus surveillance in Aedes aegypti from Recife, Brazil. J Vector Borne Dis 2010; 47: 67-75.
36. World Health Organization. March 2009, Fact sheet N°117. Dengue and Dengue haemorrhagic fever. [Online.] http://www.who.int/mediacentre/factsheets/fs117/en/
37. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19: 429-436.
38. Rico-Hesse R. Dengue virus markers of virulence and pathogenicity. Future Virol 2009; 4: 581.
39. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181: 2-9.
40. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185: 1213-1221.
41. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005; 83: 308-314.
42. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977; 265: 739-741.
43. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40: 444-451.
44. Kurane I, Mady BJ, Ennis FA. Antibody-dependent enhancement of dengue virus infection. Rev Med Virol 1991; 1: 211-221.
45. Hombach J, Cardosa ML, Sabchareon A, Vaughn DW, Barrett AD. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007; 25: 4130-4139.
46. Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008; 10: e12.
47. Sabin AB. Research on Dengue during World War II. Am J Trop Med Hyg 1952; 1: 30-50.
48. Wikramaratna PS, Simmons CP, Gupta S, Recker M. The effects of tertiary and quaternary infections on the epidemiology of dengue. PLoS One 2010; 5. pii: e12347.
49. Mathews JH, Roehrig JT. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 1984; 132: 1533-1537.
50. Gould EA, Buckley A, Barrett AD, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 1986; 67: 591-595.
51. Kaufman BM, Summers PL, Dubois DR, Eckels KH. Monoclonal antibodies against dengue 2 virus Eglycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987; 36: 427-434.
52. Kimura-Kuroda J, Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 1988; 141: 3606-3610.
53. Mason PW, Dalrymple JM, Gentry MK, et al. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol 1989; 70: 2037-2049.
54. Kaufman BM, Summers PL, Dubois DR, et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1989; 41: 576-580.
55. Schlesinger JJ, Brandriss MW, Walsh EE. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol 1985; 135: 2805-2809.
56. Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol 1988; 69: 2101-2107.
57. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66: 264-272.
58. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23: 99-109.
59. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69(6 Suppl): 48-60.
60. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69(6 Suppl): 24-31.
61. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008; 78: 426-433.
62. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005; 83: 308-314.
63. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two liveattenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006; 24: 1238-1241.
64. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009; 80: 302-311.
65. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin 2009; 5: 33-40.
66. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73: 3095-3101.
67. Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000; 74: 3020-3028.
68. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001;
69. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298: 146-159.
70. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78: 4761-4775.
71. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2: 60-67.
72. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine develop ment. J Virol 2003; 77: 11436-11447.
73. Seligman SJ, Gould EA. Live flavivirus vaccines: reasons for caution. Lancet 2004; 363: 2073-2075.
74. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70: 3930-3937.
75. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65: 405-413.
76. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191: 710-718.
77. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77: 1653-1657.
78. Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006; 2: 167-173.
79. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004; 4: 39.
80. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004; 71: 811-821.
81. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79: 5516-5528.
82. Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, Hanley KA, Murphy BR, Whitehead SS. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4. Vaccine 2008; 26: 817-828.
83. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79: 678-684.
84. Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg 2009; 81: 834-841.
85. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60: 421-467.
86. Morens DM, Halstead SB, Marchette NJ. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb Pathog 1987; 3: 231-237.
87. Yamanaka A, Kosugi S, Konishi E. Infection-enhancing and-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 2008; 82: 927-937.
88. Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I. Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA. J Virol Methods 2010; 163: 205-209.
89. Konishi E, Tabuchi Y, Yamanaka A. A simple assay system for infection-enhancing and-neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 2010; 163: 360-367.
90. Raut CG, Deolankar RP, Kolhapure RM, Goverdhan MK. Susceptibility of laboratory-bred rodents to the experimental infection with dengue virus type 2. Acta Virol 1996; 40: 143-146.
91. Paes MV, Pinhao AT, Barreto DF, et al. Liver injury and viremia in mice infected with dengue-2 virus. Virology 2005; 338: 236-246.
92. Chen HC, Lai SY, Sung JM, et al. Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol 2004; 73: 419-431.
93. Chen HC, Hofman FM, Kung JT, Lin YD, Wu-Hsieh BA. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virusinduced hemorrhage. J Virol 2007; 81: 5518-5526.
94. Huang KJ, Li SY, Chen SC, et al. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J Gen Virol 2000; 81: 2177-2182.
95. Wu SJ, Hayes CG, Dubois DR, et al. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am J Trop Med Hyg 1995; 52: 468-476.
96. Lin YL, Liao CL, Chen LK, et al. Study of Dengue Virus Infection in SCID Mice Engraftedwith Human K562 Cells. J Virol 1998; 72: 9729-9737.
97. An J, Kimura-Kuroda J, Hirabayashi Y, Yasui K. Development of a novel mouse model for dengue virus infection. Virology 1999; 263: 70-77.
98. Blaney JE Jr, Johnson DH, Manipon GG, et al. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 2002; 300: 125-139.
99. Bente DA, Melkus MW, Garcia JV, Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J Virol 2005; 79: 13797-13799.
100. Kuruvilla JG, Troyer RM, Devi S, Akkina R. Dengue virus infection and immune response in humanized RAG2-/-γc-/-(RAG-hu) mice. Virology 2007; 369: 143-152.
101. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability. J Virol 2006; 80: 10208-10217.
102. Mota J, Rico-Hesse R. Humanized mice show clinical signs of dengue fever according to infecting virus genotype. J Virol 2009; 83: 8638-8645.
103. Williams KL, Zompi S, Beatty PR, Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009; 1171 Suppl 1: E12-E23.
104. Wu-Hsieh BA, Yen YT, Chen HC. Dengue hemorrhage in a mouse model. Ann N Y Acad Sci 2009; 1171 Suppl 1: E42-E47.
105. Jaiswal S, Pearson T, Friberg H, Shultz LD, Greiner DL, Rothman AL, Mathew A. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS One 2009; 4: e7251.
106. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010; 7: 128-139.
107. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, Alonso S. A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 2010; 4: e672.
108. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 1999; 73: 783-786.
109. Bente DA, Rico-Hesse R. Models of dengue virus infection. Drug Discov Today Dis Models 2006; 3: 97-103.
110. Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008; 80: 87-93.
111. Martín J, Hermida L, Castro J, Lazo L, Martínez R, Gil L, Romero Y, Puente P, Zaragoza S, Cosme K, Guzmán MG, Cardosa J, Guillén G. Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol 2009; 53: 216-223.
112. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, Perng GC. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 2010; 115: 1823-1834.